{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:35:17Z","timestamp":1792683317172,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["19014"],"award-info":[{"award-number":["19014"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["23465"],"award-info":[{"award-number":["23465"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["Special Program 5x1000"],"award-info":[{"award-number":["Special Program 5x1000"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["awards n\u00b0 9962"],"award-info":[{"award-number":["awards n\u00b0 9962"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["21147"],"award-info":[{"award-number":["21147"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07142-6","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:49:57Z","timestamp":1761925797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A machine learning model including pentraxin-3 as predictor of outcomes in community-acquired pneumonia"],"prefix":"10.1186","volume":"23","author":[{"given":"Antonio","family":"Voza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Bonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ingallinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Mastronardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Felotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Garlanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Zierold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Ghignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-236X","authenticated-orcid":false,"given":"Alberto","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"7142_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/Ijms20082004","author":"M Karakioulaki","year":"2019","unstructured":"Karakioulaki M, Stolz D. Biomarkers in pneumonia-beyond procalcitonin. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/Ijms20082004.","journal-title":"Int J Mol Sci"},{"key":"7142_CR2","doi-asserted-by":"publisher","first-page":"E45","DOI":"10.1164\/Rccm.201908-1581st","volume":"200","author":"Jp Metlay","year":"2019","unstructured":"Metlay Jp, Waterer Gw, Long Ac, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200:E45\u201367. https:\/\/doi.org\/10.1164\/Rccm.201908-1581st.","journal-title":"Am J Respir Crit Care Med"},{"key":"7142_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/Thorax-2024-222296","volume":"80","author":"I Martin-Loeches","year":"2025","unstructured":"Martin-Loeches I, Reyes Lf, Rodriguez A. Severe community-acquired pneumonia (Scap): advances in management and future directions. Thorax. 2025;80:565\u201375. https:\/\/doi.org\/10.1136\/Thorax-2024-222296.","journal-title":"Thorax"},{"key":"7142_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/Nejm199701233360402","volume":"336","author":"Mj Fine","year":"1997","unstructured":"Fine Mj, Auble Te, Yealy Dm, Hanusa Bh, Weissfeld La, Singer De, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243\u201350. https:\/\/doi.org\/10.1056\/Nejm199701233360402.","journal-title":"N Engl J Med"},{"key":"7142_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/Thorax.58.5.377","volume":"58","author":"WS Lim","year":"2003","unstructured":"Lim WS, Van Der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377\u201382. https:\/\/doi.org\/10.1136\/Thorax.58.5.377.","journal-title":"Thorax"},{"key":"7142_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/Bf01709751","volume":"22","author":"V Jl","year":"1996","unstructured":"Jl V, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The sofa (sepsis-related organ failure assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine. Intensive Care Med. 1996;22:707\u201310. https:\/\/doi.org\/10.1007\/Bf01709751.","journal-title":"Intensive Care Med"},{"key":"7142_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1183\/23120541.00051-2023","volume":"9","author":"AG Kaal","year":"2023","unstructured":"Kaal AG, Op De Op De Hoek L, Hochheimer DT, Brouwers C, Wiersinga WJ, Snijders D, et al. Outcomes of community-acquired pneumonia using the pneumonia severity index versus the Curb-65 in routine practice of emergency departments. ERJ Open Res. 2023;9:51. https:\/\/doi.org\/10.1183\/23120541.00051-2023.","journal-title":"ERJ Open Res"},{"key":"7142_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3343\/Alm.2014.34.4.263","volume":"34","author":"M Meisner","year":"2014","unstructured":"Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;34:263\u201373. https:\/\/doi.org\/10.3343\/Alm.2014.34.4.263.","journal-title":"Ann Lab Med"},{"key":"7142_CR9","first-page":"1","volume":"97","author":"J Hedlund","year":"1995","unstructured":"Hedlund J. Community-acquired pneumonia requiring hospitalisation. Factors of importance for the short-and long term prognosis. Scand J Infect Dis. 1995;97:1\u201360.","journal-title":"Scand J Infect Dis"},{"key":"7142_CR10","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.2174\/1568026622666220401140737","volume":"22","author":"S Quintero-Fabian","year":"2022","unstructured":"Quintero-Fabian S, Bandala C, Pichardo-Macias LA, Contreras-Garcia IJ, Gomez-Manzo S, Hernandez-Ochoa B, et al. Vitamin D and its possible relationship to neuroprotection in Covid-19: evidence in the literature. Curr Top Med Chem. 2022;22:1346\u201368. https:\/\/doi.org\/10.2174\/1568026622666220401140737.","journal-title":"Curr Top Med Chem"},{"key":"7142_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/Biomedicines9050509","author":"J Oristrell","year":"2021","unstructured":"Oristrell J, Oliva Jc, Subirana I, Casado E, Dominguez D, Toloba A, et al. Association of calcitriol supplementation with reduced Covid-19 mortality in patients with chronic kidney disease: a population-based study. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/Biomedicines9050509.","journal-title":"Biomedicines"},{"key":"7142_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/S41584-023-00944-2","volume":"19","author":"M Cutolo","year":"2023","unstructured":"Cutolo M, Smith V, Paolino S, Gotelli E. Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19. Nat Rev Rheumatol. 2023;19:265\u201387. https:\/\/doi.org\/10.1038\/S41584-023-00944-2.","journal-title":"Nat Rev Rheumatol"},{"key":"7142_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/S12879-016-1566-3","volume":"16","author":"D Liu","year":"2016","unstructured":"Liu D, Xie L, Zhao H, Liu X, Cao J. Prognostic value of mid-regional pro-adrenomedullin (Mr-Proadm) in patients with community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:232. https:\/\/doi.org\/10.1186\/S12879-016-1566-3.","journal-title":"BMC Infect Dis"},{"key":"7142_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/J.Ejim.2021.03.041","volume":"88","author":"J Gonzalez Del Castillo","year":"2021","unstructured":"Gonzalez Del Castillo J, Clemente-Callejo C, Llopis F, Irimia A, Oltra-Hostalet F, Rechner C, et al. Midregional proadrenomedullin safely reduces hospitalization in a low severity cohort with infections in the ed: a randomized controlled multi-centre interventional pilot study. Eur J Intern Med. 2021;88:104\u201313. https:\/\/doi.org\/10.1016\/J.Ejim.2021.03.041.","journal-title":"Eur J Intern Med"},{"key":"7142_CR15","doi-asserted-by":"publisher","first-page":"R96","DOI":"10.1186\/Cc4955","volume":"10","author":"M Christ-Crain","year":"2006","unstructured":"Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [Isrctn04176397]. Crit Care. 2006;10:R96. https:\/\/doi.org\/10.1186\/Cc4955.","journal-title":"Crit Care"},{"key":"7142_CR16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/Emermed-2012-201872.5","volume":"29","author":"D Hodgson","year":"2012","unstructured":"Hodgson D, Nee P, Sultan L. Towards evidence-based emergency medicine: best bets from the manchester royal infirmary bet 4: prognostic value of B-type natriuretic peptides (Bnp and Nt-Probnp) in community-acquired pneumonia. Emerg Med J. 2012;29:856\u20137. https:\/\/doi.org\/10.1136\/Emermed-2012-201872.5.","journal-title":"Emerg Med J"},{"key":"7142_CR17","doi-asserted-by":"publisher","first-page":"E116","DOI":"10.1164\/Rccm.201810-1895st","volume":"198","author":"Ac Wu","year":"2018","unstructured":"Wu Ac, Kiley Jp, Noel Pj, Amur S, Burchard Eg, Clancy Jp, et al. Current status and future opportunities in lung precision medicine research with a focus on biomarkers. An American thoracic society\/national heart, lung, and blood institute research statement. Am J Respir Crit Care Med. 2018;198:E116\u201336. https:\/\/doi.org\/10.1164\/Rccm.201810-1895st.","journal-title":"Am J Respir Crit Care Med"},{"key":"7142_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/Annurev-Immunol-030409-101305","volume":"28","author":"B Bottazzi","year":"2010","unstructured":"Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010;28:157\u201383. https:\/\/doi.org\/10.1146\/Annurev-Immunol-030409-101305.","journal-title":"Annu Rev Immunol"},{"key":"7142_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1152\/Physrev.00016.2017","volume":"98","author":"C Garlanda","year":"2018","unstructured":"Garlanda C, Bottazzi B, Magrini E, Inforzato A, Mantovani A. Ptx3, a humoral pattern recognition molecule, in innate immunity, tissue repair, and cancer. Physiol Rev. 2018;98:623\u201339. https:\/\/doi.org\/10.1152\/Physrev.00016.2017.","journal-title":"Physiol Rev"},{"key":"7142_CR20","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.3389\/Fimmu.2018.02382","volume":"9","author":"Mb Pepys","year":"2018","unstructured":"Pepys Mb. The pentraxins 1975\u20132018: serendipity, diagnostics and drugs. Front Immunol. 2018;9:2382. https:\/\/doi.org\/10.3389\/Fimmu.2018.02382.","journal-title":"Front Immunol"},{"key":"7142_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/Nejmra2206346","volume":"388","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Garlanda C. Humoral innate immunity and acute-phase proteins. N Engl J Med. 2023;388:439\u201352. https:\/\/doi.org\/10.1056\/Nejmra2206346.","journal-title":"N Engl J Med"},{"key":"7142_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/S41590-021-01114-W","volume":"23","author":"M Stravalaci","year":"2022","unstructured":"Stravalaci M, Pagani I, Paraboschi Em, Pedotti M, Doni A, Scavello F, et al. Recognition and inhibition of Sars-Cov-2 by humoral innate immunity pattern recognition molecules. Nat Immunol. 2022;23:275\u201386. https:\/\/doi.org\/10.1038\/S41590-021-01114-W.","journal-title":"Nat Immunol"},{"key":"7142_CR23","doi-asserted-by":"publisher","first-page":"6966","DOI":"10.1038\/S41467-024-51047-9","volume":"15","author":"S Delliere","year":"2024","unstructured":"Delliere S, Chauvin C, Wong S, Gressler M, Possetti V, Parente R, et al. Interplay between host humoral pattern recognition molecules controls undue immune responses against Aspergillus fumigatus. Nat Commun. 2024;15:6966. https:\/\/doi.org\/10.1038\/S41467-024-51047-9.","journal-title":"Nat Commun"},{"key":"7142_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/S41590-020-00832-X","volume":"22","author":"E Brunetta","year":"2021","unstructured":"Brunetta E, Folci M, Bottazzi B, De Santis M, Gritti G, Protti A, et al. Macrophage expression and prognostic significance of the long pentraxin Ptx3 in Covid-19. Nat Immunol. 2021;22:19\u201324. https:\/\/doi.org\/10.1038\/S41590-020-00832-X.","journal-title":"Nat Immunol"},{"key":"7142_CR25","doi-asserted-by":"publisher","first-page":"105372","DOI":"10.1016\/J.Ebiom.2024.105372","volume":"108","author":"F Scavello","year":"2024","unstructured":"Scavello F, Brunetta E, Mapelli SN, Nappi E, Garcia Martin ID, Sironi M, et al. The long pentraxin Ptx3 serves as an early predictive biomarker of co-infections in Covid-19. EBioMedicine. 2024;108:105372. https:\/\/doi.org\/10.1016\/J.Ebiom.2024.105372.","journal-title":"EBioMedicine"},{"key":"7142_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/Shk.0b013e31817fd543","volume":"31","author":"T Sprong","year":"2009","unstructured":"Sprong T, Peri G, Neeleman C, Mantovani A, Signorini S, Van Der Meer JW, et al. Pentraxin 3 and C-reactive protein in severe meningococcal disease. Shock. 2009;31:28\u201332. https:\/\/doi.org\/10.1097\/Shk.0b013e31817fd543.","journal-title":"Shock"},{"key":"7142_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/Eci.12704","volume":"47","author":"P Caironi","year":"2017","unstructured":"Caironi P, Masson S, Mauri T, Bottazzi B, Leone R, Magnoli M, et al. Pentraxin 3 in patients with severe sepsis or shock: the Albios trial. Eur J Clin Invest. 2017;47:73\u201383. https:\/\/doi.org\/10.1111\/Eci.12704.","journal-title":"Eur J Clin Invest"},{"key":"7142_CR28","doi-asserted-by":"publisher","first-page":"979232","DOI":"10.3389\/Fimmu.2022.979232","volume":"13","author":"S Davoudian","year":"2022","unstructured":"Davoudian S, Piovani D, Desai A, Mapelli Sn, Leone R, Sironi M, et al. A cytokine\/Ptx3 prognostic index as a predictor of mortality in sepsis. Front Immunol. 2022;13:979232. https:\/\/doi.org\/10.3389\/Fimmu.2022.979232.","journal-title":"Front Immunol"},{"key":"7142_CR29","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/S00134-010-1752-5","volume":"36","author":"T Mauri","year":"2010","unstructured":"Mauri T, Bellani G, Patroniti N, Coppadoro A, Peri G, Cuccovillo I, et al. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med. 2010;36:621\u20139. https:\/\/doi.org\/10.1007\/S00134-010-1752-5.","journal-title":"Intensive Care Med"},{"key":"7142_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/S13054-022-04032-X","volume":"26","author":"G Wang","year":"2022","unstructured":"Wang G, Jiang C, Fang J, Li Z, Cai H. Pentraxin-3 as a predictive marker of mortality in sepsis: an updated systematic review and meta-analysis. Crit Care. 2022;26:167. https:\/\/doi.org\/10.1186\/S13054-022-04032-X.","journal-title":"Crit Care"},{"key":"7142_CR31","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1097\/00003246-200107000-00017","volume":"29","author":"B Muller","year":"2001","unstructured":"Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, et al. Circulating levels of the long pentraxin Ptx3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29:1404\u20137. https:\/\/doi.org\/10.1097\/00003246-200107000-00017.","journal-title":"Crit Care Med"},{"key":"7142_CR32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/J.Jinf.2020.01.010","volume":"80","author":"Cb Hansen","year":"2020","unstructured":"Hansen Cb, Bayarri-Olmos R, Kristensen Mk, Pilely K, Hellemann D, Garred P. Complement related pattern recognition molecules as markers of short-term mortality in intensive care patients. J Infect. 2020;80:378\u201387. https:\/\/doi.org\/10.1016\/J.Jinf.2020.01.010.","journal-title":"J Infect"},{"key":"7142_CR33","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/Atvbaha.108.178947","volume":"29","author":"J Ns","year":"2009","unstructured":"Ns J, Am A, Kuller Lh, Rp T, Bm P. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2009;29:594\u20139. https:\/\/doi.org\/10.1161\/Atvbaha.108.178947.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7142_CR34","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3389\/Fimmu.2019.00823","volume":"10","author":"G Ristagno","year":"2019","unstructured":"Ristagno G, Fumagalli F, Bottazzi B, Mantovani A, Olivari D, Novelli D, et al. Pentraxin 3 in cardiovascular disease. Front Immunol. 2019;10:823. https:\/\/doi.org\/10.3389\/Fimmu.2019.00823.","journal-title":"Front Immunol"},{"key":"7142_CR35","doi-asserted-by":"publisher","first-page":"626343","DOI":"10.3389\/Fimmu.2020.626343","volume":"11","author":"B Brilland","year":"2020","unstructured":"Brilland B, Vinatier E, Subra JF, Jeannin P, Augusto JF, Delneste Y. Anti-pentraxin antibodies in autoimmune diseases: bystanders or pathophysiological actors? Front Immunol. 2020;11:626343. https:\/\/doi.org\/10.3389\/Fimmu.2020.626343.","journal-title":"Front Immunol"},{"key":"7142_CR36","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1515\/Cclm-2012-0459","volume":"51","author":"Sj Kao","year":"2013","unstructured":"Kao Sj, Yang Hw, Tsao Sm, Cheng Cw, Bien My, Yu Mc, et al. Plasma long pentraxin 3 (Ptx3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia. Clin Chem Lab Med. 2013;51:907\u201313. https:\/\/doi.org\/10.1515\/Cclm-2012-0459.","journal-title":"Clin Chem Lab Med"},{"key":"7142_CR37","unstructured":"Confidence Intervals for Xgboost Uttar Pradesh. https:\/\/www.geeksforgeeks.org\/machine-learning\/confidence-interval-for-xgboost-regression-in-r\/"},{"key":"7142_CR38","unstructured":"Welcome to the Shap Documentation. https:\/\/shap.readthedocs.io\/En\/Latest\/"},{"key":"7142_CR39","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/J.Chest.2020.07.089","volume":"158","author":"MW Pletz","year":"2020","unstructured":"Pletz MW, Blasi F, Chalmers JD, Dela Cruz CS, Feldman C, Luna CM, et al. International perspective on the new 2019 American thoracic society\/infectious diseases society of america community-acquired pneumonia guideline: a critical appraisal by a global expert panel. Chest. 2020;158:1912\u20138. https:\/\/doi.org\/10.1016\/J.Chest.2020.07.089.","journal-title":"Chest"},{"key":"7142_CR40","unstructured":"Xgboost Documentation. https:\/\/xgboost.readthedocs.io\/En\/Stable\/"},{"key":"7142_CR41","doi-asserted-by":"publisher","first-page":"E188","DOI":"10.7861\/Fhj.2021-0095","volume":"8","author":"J Bajwa","year":"2021","unstructured":"Bajwa J, Munir U, Nori A, Williams B. Artificial intelligence in healthcare: transforming the practice of medicine. Future Healthc J. 2021;8:E188\u201394. https:\/\/doi.org\/10.7861\/Fhj.2021-0095.","journal-title":"Future Healthc J"},{"key":"7142_CR42","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1007\/S12325-022-02180-8","volume":"39","author":"Rr Watkins","year":"2022","unstructured":"Watkins Rr. Using precision medicine for the diagnosis and treatment of viral pneumonia. Adv Ther. 2022;39:3061\u201371. https:\/\/doi.org\/10.1007\/S12325-022-02180-8.","journal-title":"Adv Ther"},{"key":"7142_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/Fimmu.2018.00292","author":"C Geven","year":"2018","unstructured":"Geven C, Kox M, Pickkers P. Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/Fimmu.2018.00292.","journal-title":"Front Immunol"},{"key":"7142_CR44","doi-asserted-by":"publisher","first-page":"938801","DOI":"10.3389\/Fpubh.2022.938801","volume":"10","author":"Cy Effah","year":"2022","unstructured":"Effah Cy, Miao R, Drokow Ek, Agboyibor C, Qiao R, Wu Y, et al. Machine learning-assisted prediction of pneumonia based on non-invasive measures. Front Public Health. 2022;10:938801. https:\/\/doi.org\/10.3389\/Fpubh.2022.938801.","journal-title":"Front Public Health"},{"key":"7142_CR45","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1515\/Cclm.2009.110","volume":"47","author":"K Yamasaki","year":"2009","unstructured":"Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K. Determination of physiological plasma pentraxin 3 (Ptx3) levels in healthy populations. Clin Chem Lab Med. 2009;47:471\u20137. https:\/\/doi.org\/10.1515\/Cclm.2009.110.","journal-title":"Clin Chem Lab Med"},{"key":"7142_CR46","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1161\/01.Cir.102.6.636","volume":"102","author":"G Peri","year":"2000","unstructured":"Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. Ptx3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636\u201341. https:\/\/doi.org\/10.1161\/01.Cir.102.6.636.","journal-title":"Circulation"},{"key":"7142_CR47","doi-asserted-by":"publisher","first-page":"106599","DOI":"10.1016\/J.Jinf.2025.106599","volume":"91","author":"W Bauer","year":"2025","unstructured":"Bauer W, Galtung N, Geserick P, Friedrich K, Weber M, Somasundaram R, et al. Pentraxin-3, Myd88, Glp-1, And Pd-L1: performance assessment and composite algorithmic analysis for sepsis identification. J Infect. 2025;91:106599. https:\/\/doi.org\/10.1016\/J.Jinf.2025.106599.","journal-title":"J Infect"},{"key":"7142_CR48","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/S12879-025-10821-W","volume":"25","author":"Y Jin","year":"2025","unstructured":"Jin Y, Guo S, Xiao Y, Yin C. Assessment of the diagnostic significance of Pentraxin-3 in conjunction with procalcitonin (Pct) and C-reactive protein (Crp) for neonatal sepsis. BMC Infect Dis. 2025;25:401. https:\/\/doi.org\/10.1186\/S12879-025-10821-W.","journal-title":"BMC Infect Dis"},{"key":"7142_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2478\/Rjim-2024-0013","volume":"62","author":"D Dimitropoulos","year":"2024","unstructured":"Dimitropoulos D, Karmpadakis M, Paraskevas T, Michailides C, Lagadinou M, Platanaki C, et al. Inflammatory biomarker-based clinical practice in patients with pneumonia: a systematic review of randomized controlled trials. Rom J Intern Med. 2024;62:241\u201359. https:\/\/doi.org\/10.2478\/Rjim-2024-0013.","journal-title":"Rom J Intern Med"},{"key":"7142_CR50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.36469\/Jheor.2022.33951","volume":"9","author":"O Ericson","year":"2022","unstructured":"Ericson O, Hjelmgren J, Sj\u00f6vall F, S\u00f6derberg J, Persson I. The potential cost and cost-effectiveness impact of using a machine learning algorithm for early detection of sepsis in intensive care units in Sweden. J Health Econ Outcomes Res. 2022;9:101\u201310. https:\/\/doi.org\/10.36469\/Jheor.2022.33951.","journal-title":"J Health Econ Outcomes Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07142-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07142-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07142-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:49:59Z","timestamp":1761925799000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07142-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7142"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07142-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of Humanitas Research Hospital, approval n\u00b0 2085\/2021. The trial is registered at ClinicalTrials.gov (NCT06491004)\n                      .\n                      All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FB, PI, EG, CM, CR, CZ, and GG\u00a0are employees of Diasorin,\u00a0a\u00a0manufacturer of in vitro diagnostic tests, including PTX3. AV has received consulting fees and honoraria from SILDEHA PHARMA, GSK, Angelini and Astra Zeneca, all not related to the submitted work. SA has received consulting fees, unrelated to the submitted work, from INSMED, ZAMBON, AstraZeneca, Menarini, Behring GmbH, Pfizer, Fondazione Internazionale Menarini, Moderna, Boehringer Ingelheim, Chiesi farmaceutica, MSD Italia, Vertex Pharmaceuticals, BRAHMS GMBH, Physioassist, AN2 Therapeutics, GlaxoSmithKline. Outside the submitted work, SA has also received funding for scientific advisory boards, travel, and speaker honoraria from GlaxoSmithKline, Fondazione Internazionale Menarini, INSMED, Boehringer Ingelheim, AstraZeneca UK, Zambon, Vertex Pharmaceuticals, MSD Italia, Verona pharma. Finally, a research grant non related to the submitted work was paid by GSK directly to the Institution of SA. AM is consultant\/advisory board member for Novartis, Roche, Ventana, Pierre Fabre, Verily, Abbvie, BMS, J&J, Imcheck, Myeloid Therapeutics, Astra Zeneca, Biovelocita, BG Fund, Third Rock Venture, Biolegend Verseau Therapeutics, Macrophage pharma, Ellipses Pharma, Olatec Therapeutics, Moderna, Henlius, Myeloid therapeutics. These activities were not related to the submitted work. AM, CG, BB have IP and royalties related to PTX3. All other Authors do not have competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1205"}}